병원 감염 치료제 시장 : 약물 유형별, 감염 질환별 - 세계 예측(2025-2030년)

The Hospital Infection Therapeutics Market was valued at USD 5.90 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 8.27%, to USD 10.29 billion by 2030.

The Hospital Infection Therapeutics market is a specialized segment of the healthcare industry focused on the treatment and management of infections acquired in hospital settings. These infections, often termed nosocomial or healthcare-associated infections (HAIs), include conditions such as MRSA, C. difficile, and bloodstream infections. The necessity for such therapeutics has risen due to the increasing incidence of HAIs, which contribute to prolonged hospital stays, higher healthcare costs, and significant mortality rates. The application of hospital infection therapeutics spans antibiotics, antiviral, and antifungal agents, used primarily in hospital environments by clinicians specializing in infectious diseases. End-use sectors include hospitals, clinics, and specialized infection treatment centers. Key growth factors influencing this market include the growing geriatric population, increasing surgical procedures, and advancements in diagnostic tools leading to early detection. Moreover, government initiatives aimed at infection prevention and control create potential for market expansion. Recent biotechnology innovations and the advent of AI in drug discovery present promising opportunities. However, market growth faces challenges such as antibiotic resistance and stringent regulatory approvals, which can delay product launches and innovation. Innovations in this market are likely to focus on developing new antimicrobial agents, alternative therapies like phage therapy, and rapid diagnostic tests that enhance treatment efficacy. Strategic collaborations among pharmaceutical companies and research institutions can help overcome limitations such as high R&D costs. Business growth is feasible through investments in R&D, especially in personalized medicine approaches tailored to patient-specific infection profiles. Additionally, leveraging big data analytics can provide insights into infection patterns, optimizing therapeutic interventions. The market is competitive, driven by continuous need for improved therapeutics, and necessitates agile innovation to address emerging infection challenges and regulatory landscapes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hospital Infection Therapeutics Market

The Hospital Infection Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing geriatric population with the increase in the number of chronic diseases
  • Rapidly growing emphasis on infection control policies
  • Improvements in reimbursement policies
• Market Restraints
  • Concerns related to product recalls
• Market Opportunities
  • Increasing investments in R&D on hospital infection therapeutics
  • Favorable drug and medication approvals by government
• Market Challenges
  • Stringent Regulatory Requirements for Hospital Acquired Infection

Porter's Five Forces: A Strategic Tool for Navigating the Hospital Infection Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hospital Infection Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hospital Infection Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hospital Infection Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hospital Infection Therapeutics Market

A detailed market share analysis in the Hospital Infection Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hospital Infection Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hospital Infection Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hospital Infection Therapeutics Market

A strategic analysis of the Hospital Infection Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hospital Infection Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., and Spero Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Hospital Infection Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antibacterial Drugs, Antifungal Drugs, and Antiviral Drugs.
• Based on Infections, market is studied across Bloodstream Infections, Gastrointestinal Disorders, Hospital-Acquired Pneumonia, Surgical Site Infections, and Urinary Tract Infection.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing geriatric population with the increase in the number of chronic diseases
    • 5.1.1.2. Rapidly growing emphasis on infection control policies
    • 5.1.1.3. Improvements in reimbursement policies
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns related to product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing investments in R&D on hospital infection therapeutics
    • 5.1.3.2. Favorable drug and medication approvals by government
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulatory Requirements for Hospital Acquired Infection
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hospital Infection Therapeutics Market, by Drug Type

• 6.1. Introduction
• 6.2. Antibacterial Drugs
• 6.3. Antifungal Drugs
• 6.4. Antiviral Drugs

7. Hospital Infection Therapeutics Market, by Infections

• 7.1. Introduction
• 7.2. Bloodstream Infections
• 7.3. Gastrointestinal Disorders
• 7.4. Hospital-Acquired Pneumonia
• 7.5. Surgical Site Infections
• 7.6. Urinary Tract Infection

8. Americas Hospital Infection Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Hospital Infection Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Hospital Infection Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. AstraZeneca PLC
• 4. Basilea Pharmaceutica Ltd.
• 5. Bayer AG
• 6. Bristol Myers Squibb Company
• 7. Daiichi Sankyo Company, Limited
• 8. F. Hoffmann-La Roche Ltd.
• 9. Gilead Sciences Inc.
• 10. GlaxoSmithKline PLC
• 11. Johnson & Johnson Services Inc.
• 12. Merck & Co., Inc.
• 13. Pfizer Inc.
• 14. Sanofi S.A.
• 15. Spero Therapeutics